Table 1

Patient characteristics

CharacteristicNo. of patients (N = 316)%
Median age, y 66 (33-90)  
Median LDH, U/L (range; n = 243) 338 (136-1432) — 
Median β2-microglobulin, mg/L (range; n = 294) 2.2 (0.36-14.3) — 
Sex   
    Male 177 56.0 
    Female 139 44.0 
Binet stage (n = 289)   
    A 242 83.7 
    B-C 47 16.3 
BM pattern (n = 149)   
    Not diffuse 125 83.9 
    Diffuse 24 16.1 
IGHV mutational status (n = 268)   
    Mutated (≥ 2%) 184 68.7 
    Unmutated (< 2%) 84 31.3 
CD38 (n = 308)   
    CD38 (< 30%) 233 75.6 
    CD38+ (≥ 30%) 75 24.4 
ZAP-70 (n = 264)   
    ZAP-70 (< 20%) 160 60.6 
    ZAP-70+ (≥ 20%) 104 39.4 
CD49d (n = 164)   
    CD49d (< 30%) 106 64.6 
    CD49d+ (≥ 30%) 58 35.4 
FISH stratification (n = 298)*   
    Low-risk 211 70.8 
    Intermediate/high-risk 87 29.2 
Previous treatment   
    Yes 42 13.3 
    No 274 86.7 
CharacteristicNo. of patients (N = 316)%
Median age, y 66 (33-90)  
Median LDH, U/L (range; n = 243) 338 (136-1432) — 
Median β2-microglobulin, mg/L (range; n = 294) 2.2 (0.36-14.3) — 
Sex   
    Male 177 56.0 
    Female 139 44.0 
Binet stage (n = 289)   
    A 242 83.7 
    B-C 47 16.3 
BM pattern (n = 149)   
    Not diffuse 125 83.9 
    Diffuse 24 16.1 
IGHV mutational status (n = 268)   
    Mutated (≥ 2%) 184 68.7 
    Unmutated (< 2%) 84 31.3 
CD38 (n = 308)   
    CD38 (< 30%) 233 75.6 
    CD38+ (≥ 30%) 75 24.4 
ZAP-70 (n = 264)   
    ZAP-70 (< 20%) 160 60.6 
    ZAP-70+ (≥ 20%) 104 39.4 
CD49d (n = 164)   
    CD49d (< 30%) 106 64.6 
    CD49d+ (≥ 30%) 58 35.4 
FISH stratification (n = 298)*   
    Low-risk 211 70.8 
    Intermediate/high-risk 87 29.2 
Previous treatment   
    Yes 42 13.3 
    No 274 86.7 

LDH indicates lactate dehydrogenase; and —, not applicable.

*

Low-risk cytogenetic indicates no abnormalities or 13q−; Intermediate/high-risk cytogenetic, 11q−, 17p−, or trisomy 12.

or Create an Account

Close Modal
Close Modal